Question to the Department of Health and Social Care:

To ask Her Majesty's Government when they expect to receive a report from the National Institute for Clinical Excellence on the (1) efficacy, and (2) cost effectiveness, of the daratumumab treatment for myeloma; how long that evaluation has been in progress; and when this treatment is likely to be fully funded for the treatment of patients in the NHS.

Daratumumab has been appraised by the National Institute for Health and Care Excellence (NICE) in several different indications related to different stages of multiple myeloma and in combination with other treatments. NICE has been able to recommend daratumumab for use in several indications and it is now routinely available to eligible patients in line with NICE’s recommendations. A number of appraisals of daratumumab for use in the treatment of multiple myeloma are in development.